Hi! 👋 We have a new venture. Please check out Satire Labs, our Medium post, and consider buying our first NFT, "Dumb" SolPunks 😉.
The funniest way to turn your $100 to $1 million. ⛴️ 🚢.
Note: This is a joke. Kinda. We really do think you'll make money 😎🙂

What is ALXN's Total Other Income/Expenses?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1996 - 2021 (26 years)

Total Other Income/Expenses is 
-$1.3B (1Y +11.1% )

ALXN Stock Price & Total Other Income/Expenses

Total Other Income/Expenses for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Total Other Income/Expenses

chevron_right 2021 -$28.7M +56.4x *
( +16.9% / year avg)
chevron_left 1996 $500.0K
vertical_align_top Peak $7.1M +1.0x *
vertical_align_bottom Bottom -$2.1B
arrow_drop_up # Up Years 10 10 of 26
years up.
arrow_drop_down # Down Years 16
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1996 , or -0.77x the rate relative to it's total other income/expenses over the same period.
  • If ALXN grows it's stock at the same rate as it's total other income/expenses (+16.9%/year) , it's stock price will grow +476% and hit $518.15 over the next 10 years.
  • ALXN's stock price has gone up 5 of the 10 years (+50%) it's total other income/expenses were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Total Other Income/Expenses Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Total Other Income/Expenses YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $-28 -98.6% $108.72 -4.8%
    4/1/2020 $-2,079 495.1% $114.22 13.4%
    4/1/2019 $-349 -57.9% $100.76 -17.6%
    4/1/2018 $-829 247.7% $122.24 -14.2%
    4/1/2017 $-238 812.7% $142.41 -5.6%
    4/1/2016 $-26 -80.6% $150.9 -7.9%
    4/1/2015 $-134 138.0% $163.84 -1.5%
    4/1/2014 $-56 -23.3% $166.32 70.4%
    4/1/2013 $-73 -2434.9% $97.58 7.7%
    4/1/2012 $3 -122.2% $90.57 91.0%
    4/1/2011 $-14 2476.5% $47.42 89.6%
    4/1/2010 $0 -84.5% $25.02 37.1%
    4/1/2009 $-3 -224.5% $18.25 2.3%
    4/1/2008 $2 -59.6% $17.84 46.9%
    4/1/2007 $7 33.8% $12.14 49.4%
    4/1/2006 $5 84.7% $8.13 41.1%
    4/1/2005 $2 -7.4% $5.76 23.9%
    4/1/2004 $3 -189.9% $4.65 9.4%
    4/1/2003 $-3 -282.8% $4.25 8.0%
    4/1/2002 $1 -109.0% $3.94 -34.4%
    4/1/2001 $-21 -32.1% $6.0 -66.4%
    4/1/2000 $-30 -2479.8% $17.88 633.3%
    4/1/1999 $1 -40.9% $2.44 -2.5%
    4/1/1998 $2 120.0% $2.5 -4.8%
    4/1/1997 $1 100.0% $2.62 1.2%
    4/1/1996 $0 - $2.59 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Total other income/expenses is the total of the income/expenses that are not specified in the financial statement.

    For more detailed definitions, please see Investopedia.